Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Ronny Barak appointed new CEO of CollPlant Ltd.
CollPlant developing Type I recombinant human collagen from transgenic tobacco plants


FOR IMMEDIATE RELEASE:

Rechovot, Israel, April 30, 2008 - CollPlant Ltd. is a biotechnology company specializing in the development and commercialization of novel medical products based on its plant-derived, Type I collagen and other recombinant proteins, announced today that they elected Mr. Ronny Barak as Chief Executive Officer and Director of CollPlant.

Mr. Barak, 40, has been Chief Executive Officer and General Manager of Disc-O-Tech, in Princeton, N.J. USA, since 2005 and prior to that Vice President of Sales & Marketing – Spine. While at Disc-O-Tech, together with the management team, he led the company in signing a successful acquisition transaction with Kyphon/ Medtronic Corp. Prior to Disc-O-Tech, he served as Franchise Development Group Manager- Inter-Continental Division of Boston Scientific and Vice President and Managing Director at A.M.I. Technologies, Ltd in Israel, a medium sized medical device distribution company. He holds a Bachelor of Science degree in Chemistry from the Hebrew University of Jerusalem and a Masters in Business Administration degree specializing in Marketing from The Ramat Gan College in Israel.

Commenting on his appointment, Mr. Barak said, 'I am excited about leading CollPlant as the new CEO at this stage of the Company's development. I look forward to working with the management team to promote our R&D activities, expand our operations and establish and implement the commercialization strategy.' CollPlant has put together a multidisciplinary team of scientists who have the know-how and capability to design and produce tailor made biomaterials for a broad spectrum of unmet medical needs. In view of the Company’s unique focus on biomaterials and strong technological capabilities, Mr. Barak adds, “I believe that CollPlant will be an integral part of a significant market growth both in terms of biomaterial supply and in the development of new and superior products'.

“Mr. Barak brings more than 15 years of experience in executive and leadership positions in the Medical Device industry. CollPlant will greatly benefit from Ronny's broad local and international experience which will significantly contribute to the company's success,' said Efi Cohen Arazi, Executive Chairman of CollPlant. Cohen Arazi added: 'Recently, we closed a round of funding exceeding $8 million dollars and are now moving to the next stage of our corporate development which necessitates the recruitment of a strong leader and experienced commercialization professional”.

CollPlant is one of a handful of companies in the world to have successfully developed safe, plant-derived, recombinant human collagen and other proteins overcoming many of the obstacles which have prevented competitors to commercialize their respective products. The company has proven that their Type I collagen is similar to collagen present in human tissues. They have established transgenic tobacco plant lines which successfully co-express five different genes resulting in stable, triple helical collagen molecules. Initial safety testing of CollPlant's collagen resulted in the observation of no adverse effects in an animal model.

Collagen is one of the most important proteins in the human body. Twenty-five percent of all dry material in the body is made of collagen. Tendons are almost 100% collagen, skin 70%, and bone 50%. Collagen, the scaffold of the human body, can be incorporated into a wide variety of medical applications including: orthopedics, aesthetics, plastic surgery, tissue regeneration, wound healing, burn treatment and ophthalmics with a total market value of collagen based products estimated to be several billions of dollars per year. The Company’s scientific success places it in a unique position to meet the ever-increasing unmet demand for safe recombinant human collagen. Currently, of the majority of collagen users source their collagen from cadavers, bovine, porcine and other animal-based collagen sources. Potential


Publisher Contact Information:

IDAN Communications
+972-52-554-1810
yamit@idancom.com

Company profile of CollPlant
Past press releases of CollPlant.

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.